<DOC>
	<DOCNO>NCT01093573</DOCNO>
	<brief_summary>RATIONALE : Midostaurin may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , azacitidine , work different way stop growth cancer cell , either kill cell stop dividing . Midostaurin may help azacitidine kill cancer cell make cancer cell sensitive drug . PURPOSE : This phase I/II trial study side effect best dose midostaurin give together azacitidine see well work treat elderly patient acute myelogenous leukemia .</brief_summary>
	<brief_title>Midostaurin Azacitidine Treating Elderly Patients With Acute Myelogenous Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safe tolerable dose midostaurin combination azacitidine patient acute myelogenous leukemia . ( Phase I ) II . To describe toxicity profile combination midostaurin azacitidine patient acute myelogenous leukemia . ( Phase I/II ) III . To determine complete partial response rate rate hematologic improvement midostaurin 5-azacitidine untreated acute myelogenous leukemia . ( Phase I/II ) SECONDARY OBJECTIVES : I . To describe pharmacokinetics oral midostaurin give combination azacitidine day 8-21 schedule . ( Phase I/II ) II . To correlate treatment response FLT3 mutational status descriptive fashion . ( Phase I/II ) III . To assess overall survival patient initiation midostaurin-azacitidine toxicity . ( Phase I/II ) IV . To determine median disease-free survival regimen untreated patient . ( Phase II ) TERTIARY OBJECTIVES : I . To describe signal CD117+ commit myeloid precursor whole blood bone marrow sample treatment . ( Phase I/II ) II . To measure vivo FLT3 inhibition use plasma inhibition assay ( PIA ) Flt ligand ( FL ) level patient enrol trial treatment . ( Phase I/II ) OUTLINE : This phase I , dose escalation study midostaurin follow phase II study . Patients receive azacitidine intravenously ( IV ) 10-20 minute day 1-7 midostaurin orally ( PO ) twice daily ( BID ) day 8-21 . Courses repeat every 28 day 8 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>4'-N-benzoylstaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>Inclusion Criteria Patients must histologic proof active AML time enrollment Phase I II portion : Subjects age untreated AML , candidate standard induction chemotherapy poor risk AML ( i.e . precede MDS , myeloproliferative syndrome , leukemia due cytotoxic chemotherapy another condition , adverse cytogenetics complex karyotype ) , subject &gt; 70 year age untreated AML . Acute promyelocytic leukemia ( FAB M3 ) exclude Please note : prior intensive induction therapy acute leukemia allow phase I portion study â€¢ PHASE I PORTION ONLY : Patients age receive one prior attempt induction chemotherapy ( may receive treatment consolidation ) , must recover acute toxicity therapy &gt; = 4 week last dose cytotoxic treatment ; patient receive prior autologous allogeneic stem cell transplantation eligible ; patient may receive 1 2 cycle cytarabinebased therapy attempt induction . Phase II portion : Patients must receive prior intensive induction therapy AML . Intensive induction include standard induction chemotherapy 7 &amp; 3 , high dose cytarabine , mitoxantroneetoposide , lowdose subcutaneous cytarabine . Allowed `` nonintensive '' prior treatment preexist hematologic condition ( i.e. , MDS , chronic myelomonocytic leukemia [ CMML ] ) include : hydroxyurea , thalidomide , hematopoietic growth factor , Zarnestra , Lenalidomide , arsenic , Imatinib , corticosteroid , suberoylanilide hydroxamic acid [ SAHA ] inhibitor ; hydroxyurea allow 24 hour initiate treatment control blood count first cycle chemotherapy azacitidine complete ; minimum 4 week must elapse since administration thalidomide , Zarnestra , Revlimid , arsenic , SAHA inhibitor , investigational medication ; minimum five day must elapse since administration growth factor Prior cytotoxic chemotherapy another condition treat curative intent allow provide least 18 month elapse last treatment enrollment protocol Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) = &lt; 1.5 time upper limit normal Serum bilirubin = &lt; 1.5x upper limit normal Creatinine = &lt; 1.5x upper limit normal No exclusion blood count ; however , time treatment initiation , white blood cell ( WBC ) &lt; 30,000/uL ( control hydroxyurea ) Life expectancy without treatment least 12 week Patients without FLT3 mutation eligible participate Patients must ability willingness sign write informed consent document Exclusion Criteria Acute promyelocytic leukemia ( FAB M3 ) Prior autologous allogeneic stem cell transplant Prior azacitidine , decitabine , midostaurin Patients know impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption midostaurin ; patient gastric bypass surgery exclude Patients know active cancer ( except carcinoma insitu ) , concurrent severe and/or uncontrolled medical condition ( e.g . uncontrolled diabetes , pulmonary , chronic renal disease , active uncontrolled infection ) Cardiovascular Criteria exclude patient participation study include : Screening electrocardiogram ( ECG ) QTc &gt; 450 msec ; Patients congenital long QT syndrome ; History presence sustain ventricular tachycardia ; Any history ventricular fibrillation torsades de pointes ; Bradycardia define heart rate ( HR ) &lt; 50 bpm ; Right bundle branch block + leave anterior hemiblock ( bifascicular block ) ; Patients myocardial infarction unstable angina &lt; 6 month prior start study drug ; Congestive heart failure ( CHF ) New York ( NY ) Heart Association class III IV ; Patients ejection fraction = &lt; 45 % assessed multi gate acquisition scan ( MUGA ) echocardiogram ( ECHO ) scan within 14 day day 1 Poorly control hypertension Known allergy hypersensitivity azacitidine , mannitol , midostaurin Active suspicion central nervous system ( CNS ) leukemia Patients human immunodeficiency virus ( HIV ) disease active viral hepatitis Patients hepatitis B Patients abnormal chest Xray and/or pulmonary infiltrate include suspect infectious origin ; particular , patient resolution clinical symptom pulmonary infection residual pulmonary infiltrates chest xray eligible pulmonary infiltrates completely resolve Pregnant lactate woman Prohibited medication : PKC412 two major metabolite may potential drugdrug interaction Pgp substrates CYP3A4 inhibitor , inducer . An increased anticoagulant effect note patient treated warfarin midostaurin . Patients receive investigational agent within 30 day prior day 1 Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose 3 month midostaurin medication . Highly effective contraception method include : Total abstinence ( line prefer usual lifestyle subject . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment Male sterilization ( least 6 month prior screen ) . For female subject study vasectomized male partner sole partner subject . Combination two follow ( a+b a+c , b+c ) : 1 . Use oral , injected implant hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception . 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) 3 . Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository In case use oral contraception woman stable pill minimum 3 month take study treatment Sexually active male unless use condom intercourse take drug 5 month stop midostaurin medication . They father child period . A condom require use also vasectomize men order prevent delivery drug via seminal fluid .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Untreated myelodysplastic syndrome</keyword>
</DOC>